Currently, under cGMP regulations pharmaceutical companies are not required to have written quality agreements, but the FDA is suggesting companies adopt such agreements as a preventative measure. These agreements are suggested to include a puropse/scope, effective and termination dates, dispute resolution, responsibilities, change control and revisions. Read the full story.
